Clin2
NCT07362758Possibly a fitNot yet recruiting

mRNA therapy for autoimmune diseases

Autoimmune Diseases

Part of Immune system & allergy clinical trials.

This trial tests a new mRNA treatment that targets a protein called CD19 on immune cells. It may help people with severe autoimmune diseases like lupus, ITP, or AIHA when other treatments haven't worked.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
47 people
Ages
14 years to 70 years
Study type
Interventional

Who can take part

  • You must be between 14 and 70 years old.
  • You need to be generally active and able to care for yourself (KPS score > 60).
  • If you could get pregnant or father a child, you must use reliable birth control during the study and for 30 days after.
  • You or your legal guardian must understand and sign a consent form.
  • You must have a severe, returning, or treatment-resistant autoimmune disease such as immune thrombocytopenia, autoimmune hemolytic anemia, lupus, or scleroderma.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07388212Not yet recruiting· Early Phase 1
mRNA therapy for relapsed autoimmune diseases

This early-phase trial tests an mRNA drug that targets CD19 and BCMA proteins. It aims to treat autoimmune diseases like lupus that have come back or not responded to other treatments.

NCT06762119Not yet recruiting· Early Phase 1
CAR-T cell therapy for autoimmune diseases

This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for people with certain autoimmune diseases, including lupus, scleroderma, and others. The goal is to see if the treatment can help control the disease.

Hangzhou
NCT07490951Recruiting
CAR-T cell therapy for refractory autoimmune diseases

This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.

Wuhan, Hubei
NCT06279923Recruiting· Early Phase 1
CAR-T cells for autoimmune diseases

This trial tests a new CAR-T cell therapy that targets two immune proteins (CD19 and BAFF) to treat autoimmune diseases like lupus or scleroderma. It is for people who have not improved with standard treatments.

Hangzhou, Zhejiang
NCT07040917Not yet recruiting· Early Phase 1
CAR-T cell therapy for autoimmune diseases

This trial tests whether CAR-T cells, a type of immune cell therapy, can help people with certain autoimmune diseases. If you have lupus, scleroderma, or other listed conditions, you may be able to join and see if this treatment can calm your overactive immune system.

Beijing, Beijing Municipality
NCT06680388Recruiting· Early Phase 1
CD19 CAR-T for severe autoimmune diseases

This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.

Tianjin, Tianjin Municipality

Hear when a new Autoimmune Diseases trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.